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ABSTRACT

Correlation of In-Vitro Drug Dissolution and In-Vivo Drug Absorption of Various
Therapeutically Equivalent Pharmaceutical Solid Dosage Forms of Simvastatin

Simvastatin is a well known anti-cholesterol drug that is commercially available
in the United States in various strengths including Simvastatin Tablets, USP 80 mg, that
are under the brand name Zocor (manufactured by Merck Pharmaceutical Co.) and
various generic equivalent products for example those manufactured by Teva
Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories, Ltd. When generic products are
tested in the United States, they must be found to be equivalent with their branded
products by the FDA. Therefore, generic Simvastatin Tablets, USP 80 mg, have been
tested and approved by the FDA as equivalents to, and substitutable with, the branded
Zocor tablets of the same strength. The Teva and Reddy’s generic Simvastatin products
have also been found to be bioequivalent to the branded Zocor product in FDA-approved
in-vivo clinical studies involving healthy human subjects (dosed under fasting and nonfasting conditions).
In this study, the drug dissolution profiles of the brand Zocor and the generic
Teva and Reddy’s Simvastatin 80 mg tablets were assessed and compared using twelve
different in-vitro dissolution tests consisting of three different dissolution media (i.e.,
three aqueous solutions of 0.5% w/v SLS in Phosphate Buffer pH 7.0, Purified Water, or
Acetate Buffer pH 4.5, respectively), two different volumes of dissolution medium (i.e.,
500 or 900 mL per dissolution vessel), and two different agitation speeds (i.e., paddles
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rotating at 35 or 50 rpm). The 10-min, 20-min and 30-min drug dissolution rates of each
of the two generic products were statistically compared to those of the reference Zocor
product using a t-test to evaluate similarities or significant differences between the
compared drug dissolution rates of the Teva vs. Zocor and Reddy’s vs. Zocor product
pairs under evaluation.
It was established in this study that two dissolution tests in particular possess
promising in-vitro/in-vivo correlation characteristics, which should be further evaluated.
Specifically, it was found that two dissolution tests consisting of 900 mL (per vessel) of
an aqueous dissolution medium comprising of 0.5% w/v SLS in either Phosphate Buffer
pH 7.0 or Acetate Buffer pH 4.5, maintained at 37oC and agitated via paddles rotating at
a speed of 35 rpm, have produced statistically similar 10-min, 20-min and 30-min drug
dissolution rates displayed by all three products. These results show that the use of these
two in-vitro dissolution tests may have reliable predictive in-vivo power, thereby possibly
facilitating the timely and cost-efficient development of new generic immediate-release
Simvastatin products that would be bioequivalent to their branded Zocor counterpart.
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INTRODUCTION AND LITERATURE BACKGROUND

Simvastatin
Simvastatin is a lipid-lowering drug, which is used for treating patients with
hypercholesterolemia, a form of hyperlipidemia, in order to prevent atherosclerosis,
cardiovascular disease, and stroke (Schmitz and Langmann, 2006).

Cardiovascular

disease is still the leading cause of death worldwide today (ibid.).

When diet and

exercise are not enough to reduce cholesterol levels, statins are the most prominent
medication prescribed. Cholesterol is important for the body because it aids in the
production of hormones, vitamin D and bile acids that facilitate digestion of fats in the
intestines. However, bad cholesterol, also known as low density lipoprotein (LDL),
adheres to arteries and results in the blockage of proper oxygenated blood flow.
Therefore, elevated levels of LDL increase the risk of heart disease, heart attack and
stroke. With the use of lipid-lowering therapy, however, statins have been able to
decrease mortality caused by high levels of cholesterol by inhibiting the rate-limiting step
of cholesterol biosynthesis.

Simvastatin is one of the most important and highly

commercialized representatives of the statin family, which consists of potent 3hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
Simvastatin is administered as a lipophilic lactone pro-drug and converted in-vivo
to its corresponding beta-hydroxyacid form (Figure 1). Beta-hydroxyacid is its active
metabolite, which is the inhibitor of HMG-CoA reductase.

A pro-drug is a

pharmacological substance administered in an inactive form to later be metabolized to its
active metabolite (Mitchel, 1992). Administered as a lactone pro-drug increases its
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selective uptake by the liver, which is the site of action of cholesterol biosynthesis and of
course drug metabolism.

Simvastatin’s pro-drug status also allows for low system

availability of the active drug, which also helps in lowering adverse effects (Mitchel,
1992). Another advantage is that it can be taken without regard to food (Davidson and
Toth 2004).
Simvastatin is structurally similar to and also, a semi-synthetic chemical
modification of Lovastatin (see Figure 1), with the addition of a methyl group on the ester
side chain (Boccuzzi, 2000). Simvastatin is a fermentation product of Aspergillus terreus
(Blum 1994, p. 3D). The chemical name is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8ahexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1naphthalenyl ester (Merck, 2012). Simvastatin’s empirical formula is C25H38O5, and its
molecular weight is 418.57; it’s a white to off-white, non-hygroscopic, crystalline powder
that is virtually insoluble in water, and freely soluble in methanol and ethanol (Merck,
2012). Zocor (Simvastatin Tablets, USP) is available for oral administration in 5 mg, 10
mg, 20 mg, 40 mg and 80 mg strengths in the form of tablets with the following inactive
ingredients: ascorbic acid, citric acid, hydroxypropyl cellulose, hypromellose, iron
oxides, lactose, magnesium stearate, microcrystalline cellulose, starch, talc, and titanium
dioxide (ibid.). Other commonly available forms of statins and members of the statin
family are: Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin,
Pravastatin and Rosuvastatin.
Statin therapy is the choice for individuals with high LDL cholesterol levels.
They competitively inhibit the rate-limiting step of cholesterol synthesis in the liver (see
Figure 2). Acetyl-CoA initiates the reactions that comprise the mevalonate pathway that
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leads to the production of farnesyl-PP, the precursor for cholesterol (Bentinger et al.,
2010). Statins inhibit HMG-CoA reductase from converting HMG-CoA to Mevalonic
acid.

Figure 1: Chemical structure of Simvastatin and Lovastatin (Shitara and Sugiyama,
2006; with permission of publisher).
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Figure 2: Biosynthesis of cholesterol. Cholesterol is synthesized from acetyl coenzyme
A. These drugs act by competitively inhibiting this enzyme from converting HMG-CoA
to mevalonate, which is the rate-limiting step in cholesterol biosynthesis (Shitara and
Sugiyama, 2006; with permission of publisher).

The inhibition of cholesterol synthesis by statins promotes the up-regulation of
LDL receptor expression, leading to a decrease in LDL levels in plasma. All statins
lower triglyceride levels up to 30-50%, which renders them extremely useful agents for
lipid lowering therapy (Schmitz and Langmann, 2006). It is important to note that LDL
functions to transport cholesterol away from the liver to other cells of the body, whereas
High Density Lipoprotein (HDL), the “Good Cholesterol”, functions to transport
cholesterol back to the liver. Therefore, it is imperative to take quick action against
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hyperlipidemia in order to keep LDL levels as low as possible to avoid cholesterol
buildup in the heart and to hinder further complications.
Initially, all drugs undergo biotransformation prior to entering systemic
circulation. There are two stages, the pre-hepatic where biotransformation takes place in
the intestinal wall by the columnar epithelial cells and secondly by the liver. The liver is
the epitome of drug metabolism in which all drugs are targeted to undergo first pass
metabolism (Blum, 1994). Oral bioavailability of Simvastatin is extremely low (<5%),
due to its extensive CYP3A mediated first pass metabolism in the intestinal wall and liver
(Neuvonen et al., 2006). CYP3A4 is part of the CYP 450 system involved in drug
metabolism (see Figure 3). CYP3A4 oxidizes and hydrolyzes simvastatin’s lactone form
to its inactive or moderately active metabolites (Neuvonen et al., 2006). To avoid toxic
serum levels, it is important not to use other drugs that are CYP3A4 inhibitors with
simvastatin because it will lead to strong increases in its concentrations and elicit
unwanted drug interactions (Neuvonen et al., 2006).
Adverse effects caused by statins correlate with their plasma levels. Therefore, it
is imperative to control statin plasma levels and to avoid concomitant use of statins with
CYP3A4 inhibitors or inducers. CYP3A4 inhibitors include but are not limited to,
Itraconazole, Ketoconazole, Posaconazole, HIV protease inhibitors, Boceprevir,
Telaprevir, Eythromycin, Clarithromycin, Telithromycin, Nefazodone, Verapamil,
Dilitazem, Amiodarone, Amlodipine, Ranolazine, Gemfibrozil, Cyclosporine Danazol
and grapefruit juice (Merck, 2012).
Statins are generally well-tolerated drugs with mild dyspepsia or gastrointestinal
disturbances (Neuvonen et al., 2006). There are more severe clinical conditions however,
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that consist of myotoxic adverse reactions such as myopathy and infrequently,
rhabdomyolysis (Neuvonen et al., 2006).

The probability of being diagnosed with

myopathy including rhabdomyolysis, is dose related and is greater in patients on
Simvastatin 80 mg than in lower doses (Merck, 2012). Myopathy is a form of muscle
weakness whereas rhabdomyolsis is the breakdown of muscle fibers releasing myoglobin
into the bloodstream, which has hazardous affects on the kidney (Bellosta et al., 2004).
In contrast, Rifampin, a drug used to treat tuberculosis, is a CYP3A4 inducer, which
decreases the levels of statins in plasma and prevents the patient from having a
therapeutic effect after Simvastatin administration (Neuvonen et al., 2006).

Figure 3: Drug Metabolism (after Katzung, 2009).
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The inhibitory effect of statins on HMG-CoA reductase also leads to deficiencies

in other biological molecules.

One of the molecules affected by statin therapy is,

Coenzyme Q10 (Figure 4), a ubiquitous molecule of the body, especially found in the
heart, liver, and skeletal muscles (Balakrishnan et al., 2009). A fat-soluble, vitamin-like
benzoquinone compound (Nakajima et al., 2008), Coenzyme Q10 is 2, 3-dimethoxy, 5methyl, 6-polyisoprene parabenzoquinone (Crane, 2001). Not only does it function as an
energy-producing molecule in the body, but also as an antioxidant which protects cells
from free radicals. Coenzyme Q10 is a crucial component of the electron transport chain
of oxidative phosphorylation that takes place in the mitochondria (see Figure 5). It serves
as an electron acceptor for complex I (NADH: ubiquinone oxidoreducatse) and complex
II (succinate: ubiquinone) to complex III (CoQ-cytochrome c reductase) (Shultz, 2005).
The reduction of the quinone (oxidized form) to quinol (reduced form) enables it to carry
electrons and protons (Crane, 2001).

The energy released is used by complexes I, III,

and IV to transport protons from the matrix to the intermembrane space (Shultz, 2005).
In return, this creates an electrochemical gradient to drive complex V to form adenosine
triphosphate ATP. Oxidative phosphorylation is the most efficient way of producing
adenosine triphosphate (ATP), which imparts the energy necessary for muscle
contraction and other essential cellular functions.

Complex I and II accept electrons

from NADH and FADH2 electron donors. Therefore, Coenzyme Q 10 serves as a
cofactor in the production of adenosine triphosphate (ATP) serving as an electron
acceptor (Nakajima et al., 2009).
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Figure 4: Structure of Coenzyme Q10 (after Naini, 2012).

Figure 5: Diagram of the electron transport chain (ETC) and the permeability transition
pore (PTP). Coenzyme Q10, which is the electron acceptor for complexes I and II, plays
a central role in the ETC (Shults, 2005; with permission of publisher).
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Furthermore, another biochemical function of Coenzyme Q10 is that it acts as an

antioxidant. It is conveniently located in all cell membranes in close proximity to the
unsaturated lipid chains and acts as a scavenger of free radicals. Its presence is a crucial
defense mechanism that prolongs cell life by preventing oxidative cell damage, oxidation
of proteins and lipids (Bentinger et al., 2010).

During the metabolism of oxygen,

especially in the reduction of oxygen by the electron transport chain (ETC) of
mitochondria, free radicals form and if they are not neutralized by antioxidants, then they
damage the mitochondria. Co Q10 primarily is in its reduced state, which enables it to
easily donate its electrons. Co Q10 essentially renders free radicals as harmless.
Decreased levels of Coenzyme Q10 can lead to cardiac failure and mitochondrial
defects, which reflects it’s importance in the electron transport chain.

HMG-CoA

reductase is the key enzyme that catalyzes the conversion of HMG-CoA to mevalonate,
which is an early rate-limiting step in the biosynthetic pathway of cholesterol (see Figure
2). In healthy cells, Coenzyme Q10 is synthesized from tyrosine (or phenylalanine) and
mevalonate (Crane, 2001).

Acetyl-CoA initiates the reactions that comprise the

mevalonate pathway that leads to the production of farnesyl-PP, the precursor for
cholesterol, Coenzyme Q, dolichol and isoprenylated proteins (Bentinger, 2010). Statin
drugs target this rate-limiting step where it competitively intervenes with the synthesis of
cholesterol therefore decreasing Coenzyme Q10 levels but also isoprednoids and
dolichols (Schmitz and Langmann, 2006).

Isoprenoids partake in posttranslational

modification of several proteins, and mitochondrial function (Davidson, 2004).
Dolichols levels are also affected which partake in the synthesis of oligosaccaharide
chains of glycoproteins (Schmitz and Langmann, 2006).
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Dissolution Testing
Dissolution testing has been employed for more than fifty years in the
pharmaceutical industry (Ameri et al., 2011). Dissolution rate is defined as the amount
of substance that goes into solution per unit time under standardized conditions of liquidsolid interface, solvent composition and temperature (ibid.).

Dissolution testing is

performed by placing a given drug dosage form in a liquid (usually of aqueous content)
maintained at a given temperature (usually 37°C) and agitated by various means under
regulated conditions, followed by sample collection and analysis of the samples to
establish the cumulative percentage of drug dissolved from the drug dosage form under
evaluation at fixed time points.
Dissolution is used as a tool to evaluate drug release characteristics, stability of
formulations, monitor product consistency among batches and establish in-vitro/in-vivo
correlation amongst drug products.

It is also a key analytical test utilized for the

identification of the physico-chemical properties of a drug product (Ameri et al., 2011).
In essence, dissolution testing is a valuable tool used during product development to
develop a bioequivalent product and also becomes a routine quality control test once the
FDA approves the product for commercial manufacturing.

Pharmaceutical companies

have employed it as a tool in assessing or projecting bioequivalence between a branded
drug product and it’s generic counterparts (see Figure 6). In order for a drug product to
be bioequivalent, the rate and extent of drug absorption from the test product has to be
similar to the rate and extent of drug absorption from the reference drug product when
administered at the same dose of the therapeutic ingredient under similar experimental
conditions (ibid.). A clinical bioequivalence study is necessary to show that the test and
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reference drug products behave the same way in-vivo and to get approval from the FDA
for a generic drug product. Drug products that are therapeutically equivalent must be
pharmaceutical equivalents (i.e. they should be the same dosage form, same strength and
also be bioequivalent to each other).

Figure 6: Typical dissolution bath made up of vessels and rotating paddles.

Drug absorption from a solid dosage form after oral administration depends on the
release of the drug substance from the drug product, dissolution of the drug under
physiological conditions and permeability of the dissolved drug across the
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gastrointestinal tract. Therefore, drug release and dissolution in the physiological fluids
of the gastrointestinal tract is a prerequisite for drug absorption. The Food and Drug
Administration (FDA) defines bioavailability as the rate and extent to which the active
substances or therapeutic ingredients that make up a drug product are absorbed and
become available in the systemic circulation (Tedeschi et al., 2009). Furthermore, as
discussed earlier, drug dissolution is, in many instances, the rate-limiting step to drug
absorption, because if the drug is not released and dissolved from its dosage form in the
physiological fluids of the gastrointestinal tract, then it will not become bio-available and
there will be no therapeutic effect. In essence, dissolution encompasses the course of
action of extracting the active pharmaceutical ingredient out of its solid dosage form and
dissolving it in the physiological fluids of the gastrointestinal tract. The next step,
absorption, is the process of transporting the dissolved drug substance from the
gastrointestinal lumen into the systemic circulation. Therefore, dissolution testing serves
as a very good in-vitro test to mimic the release of the drug from the dosage form and its
dissolution in the fluids of the gastrointestinal tract. This, in turn, can be used to predict
the rate and extent of actual in-vivo drug absorption and help in developing an in-vitro/invivo correlation that can predict bioequivalence amongst different drug products. In
some cases, however, it might not be feasible to develop a dissolution test that will
demonstrate a correlation between the in-vitro and in-vivo performance of a drug product
and also predict or project a reliable comparison between similar drug dosage forms.
The United States Pharmacopeia (USP) is the most commonly used reference that
sets the standards for drugs and drug products. The USP monograph for a drug product
defines the specifications, such as assay, dissolution requirements, impurity levels, etc.
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that a drug product has to maintain throughout its shelf life. Only drug products that
meet the USP monograph requirements can be designated as USP.

For example,

Simvastatin Tablets manufactured by Merck (Zocor), Teva and Dr. Reddy’s are all
designated as Simvastatin Tablets, USP 80 mg, meaning that they all meet the USP
monograph requirements.

The USP monograph for most drug products includes a

dissolution test and sets specifications for the amount of drug that has to be dissolved at a
certain time point under certain dissolution conditions. This value is defined as the “Q”
value for the dissolution of the drug product and is employed as a quality control measure
and specification for all manufactured lots of that drug product. However, the dissolution
tests recommended by the USP for regular release testing of lots of drug products usually
do not have enough discriminating power to establish an in-vitro/in-vivo correlation and
cannot be used exclusively to predict bioequivalence between different drug products of
the same drug.
Selection of the appropriate in-vitro conditions that simulate the in-vivo
environment and absorption process can lead to the production of an efficacious invivo/in-vitro correlation. The development of a dissolution test is constructed upon
several physiochemical and physiodynamic factors. The procedure involves selecting
parameters that are suitable, such as dissolution media, apparatus type, agitation rate and
surfactant concentration in the dissolution medium. Numerous factors influence drug
dissolution including: physiochemical properties of the drug (solubility), formulation
characteristics (coatings, inactive ingredients, manufacturing parameters) and the
dissolution method itself (apparatus type, volume, pH of medium, agitation rate)
(Jamzad, 2005). Surfactants, such as sodium lauryl sulfate (SLS), dissolved in the
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dissolution medium, are commonly used for dissolution tests involving poorly watersoluble drugs such as Simvastatin.
The solubility of a drug largely depends on the medium in which it must dissolve.
Simvastatin is categorized as a class II drug by the biopharmaceutics classification
system (BCS), which implies that Simvastatin has low solubility in aqueous media but
high permeability characteristics through the gastrointestinal mucosa. BCS serves as a
guide for predicting intestinal drug absorption based on solubility and permeability
parameters. Based on the above BCS classification for Simvastatin, drug release from
the dosage form and its solubility in the physiological fluids of the gastrointestinal tract
(i.e., its dissolution) are the rate- liming steps for its actual in-vivo absorption.
Simvastatin is a crystalline compound that is a water insoluble drug and
dissolution testing requires the use of surfactants in the dissolution medium (Rao et al.,
2010). Surfactants are compounds that lower the surface tension at the solid-liquid
interface between a drug particle and the dissolution media, which is a physical
determinant of the surface area available for dissolution, and also solubilize the drug by
forming micelles (Dressman and Reppas, 2000).

Therefore, surfactants such as SLS

increase a drug’s solubility in solution. In essence, surfactants are meant to mimic the
naturally occurring surfactants found in gastric juices and bile salts that enable
dissolution of water insoluble drugs (Shah, 1989).
Another important factor to consider is the sink conditions of the dissolution
media. Sink conditions require the sustainment of a volume of dissolution media that is
at least three times greater than the volume at the saturation solubility point of the drug
contained in the drug delivery system being evaluated (Rohrs, 2001). Simvastatin is
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highly permeable because it has lipophilic characteristic that allows it to cross cellular
membranes by passive diffusion (Hameline, 1998).

Moreover, passive diffusion of a

lipophilic drug such as Simvastatin ensures that the drug will be extensively metabolized
by the hepatocytes of the liver.
The pH of the dissolution medium is another important factor in dissolution
testing (see Figure 7). The human body contains an inherent pH gradient along the
gastrointestinal tract. pH dependent dissolution from a dosage form predicts where the
drug is most likely to dissolve within the gastrointestinal tract.

The stomach has a pH

that ranges from 1 to 3, which is extremely acidic in order to aid in the breakdown of
proteins. In contrast, the duodenum of the small intestine has a pH of about 5 to 6 and
the pH continues to increase along the length of the intestinal tract. The small intestine’s
increased pH levels and extremely large surface area aids in the absorption of most drugs
and nutrients. Variations of pH along the gastrointestinal tract can affect the drugs
solubility, dissolution and permeability (Lu et al., 2011).
Dissolution testing should be carried out under physiological conditions because
this allows for interpretation of dissolution data with regard to in-vivo performance of the
product. Numerous factors can have a major role in affecting dissolution rates and
percent of drug dissolved. Dissolution conditions such as apparatus type, pH of medium,
agitation speed, sink conditions, volume and surfactants added in the dissolution medium
are capable of causing differences in the dissolution characteristics between drug product
counterparts. However, another important factor are the excipients used to make up the
bulk of the total dosage form.

In essence, excipients are the inactive ingredients that

constitute the formulation of the drug product aside from the active pharmaceutical
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ingredient.

Excipients are the preservatives, colors, coating agents, flavors, solubility

enhancers, lubricants, binders and disintegrants that control the dissolution characteristics
of the drug from the dosage form.

Figure 7: pH variation along the gastrointestinal tract (Boudinot, 2012; with permission
of publisher).

Generic Drugs
A generic drug product is approved by the FDA as a therapeutic equivalent to its
corresponding branded drug product. To be approved as therapeutically equivalent, the
generic product has to be pharmaceutically equivalent (i.e., same dosage form, strength,
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same route of administration, etc.) and also be bioequivalent to the branded drug product.
In a few cases where the drugs exhibit very good solubility in the gastrointestinal fluids
and very good permeability across the gastrointestinal mucosa, the FDA may waive the
bioequivalence requirements for a generic drug but they still need to be pharmaceutically
equivalent to their corresponding branded drug products. A branded drug product is the
original drug product formulated by pharmaceutical companies. The Brand manufacturer
has already discovered the active pharmaceutical ingredient (API), and has evaluated the
therapeutic and toxicological properties of the drug. Hence, the generic drug products
have to be therapeutically equivalent to the branded drug.
Overall, in order to be approved as a generic of a branded product, a generic drug
product must be bioequivalent, and also pharmaceutically equivalent to its branded
counterpart in terms of: active ingredient, strength, purity, safety and route of
administration (Ameri et al., 2011). A dissolution test plays a key role in assessing the
bioequivalence between a generic and its branded counterpart. If the drug products are
bioequivalent and pharmaceutically equivalent, then they are therapeutically equivalent,
which means that they are suitable for substitution.
Clinical bioequivalence studies are conducted in human subjects. The brand and
generic drug products are dosed in the human subjects using a study design. The blood
samples are collected from the subjects at certain time points after the drugs are dosed.
The blood samples are analyzed for the drug content in plasma at each time point. The
drug concentration in the plasma at each time point is then determined. The drug
concentrations obtained in all the subjects after dosing the branded product and in the
same subjects after and dosing the generic product are compared statistically for certain
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parameters such as Cmax, Tmax, AUC0-t and AUC0-inf. Cmax is defined as the max plasma
concentration of a therapeutic drug and Tmax, is defined as the time at which the drug
reaches Cmax. AUC is the area under the curve starting from time point 0 till the last
sampled time. These parameters have to be within certain limits for the generic product
to be called bioequivalent to the branded drug product.
When dissolution tests are conducted during product development for generic
drug products, a dissolution profile similar to that of the brand is desired, hoping it will
have the same profile in the human body and give blood concentrations that would be
bioequivalent to that of the brand. This technique works in some cases. In other cases,
however, even if the in-vitro drug dissolution profiles are the same, the two products can
behave differently in the body. Furthermore, when dissolution results are different, the
two products may still behave the same way in the human body and be bioequivalent to
each other.
Once a generic product is approved, dissolution becomes a part of the testing for a
commercial batch before it can be released to the market. This is done to ensure that the
drug dissolution profile of each commercial batch dissolution profile is similar to that
obtained from the batch that is bioequivalent to the brand. This gives comfort that the
commercial batch is behaving exactly like the batch that was sent to the bioequivalence
study. Also, brand companies do dissolution tests on their products to see if their
commercial batches are behaving like their original FDA submission batches in order to
ensure batch-to-batch reproducibility.
Health care professionals and consumers can be certain that the FDA approved
generic drug products have met the same strict standards as the innovator drug.
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Otherwise, the drug will not be put on the market. The Current Good Manufacturing
Practice (cGMP) regulations enforced by the FDA ensures proper design, monitoring and
control of manufacturing processes and facilities (U.S. Drug and Food Administration,
2009). A generic drug is required to have the same active pharmaceutical ingredient,
strength, route of administration, dosage form and quality. The only varying factors are
the inactive ingredients used, also known as excipients, in the formulation of the drug that
regulate bioavailability, solubility, rate of drug release and that bind the drug together.
But, in general, if a company does not comply with the cGMP regulations, the drug
product is then considered “adulterated” under the law (U.S. Drug and Food
Administration, 2009).
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MATERIALS AND METHODS

Summary of Experimental Design
Three commercial products of Simvastatin USP 80 mg Tablets, namely, the brand
Zocor 80 mg tablets manufactured by Merck Pharmaceutical Company (i.e., "Zocor" of
Lot No. G004118) and two FDA-approved generics of Simvastatin 80 mg tablets
equivalent to Zocor manufactured by Teva Pharmaceuticals, Inc. (i.e., "Teva" of Lot No.
25S032) and by Dr. Reddy's Laboratories, Ltd. (i.e., "Dr. Reddy's" or "Reddy's" of Lot
No. C105447), were tested for their drug dissolution profiles using twelve (12) different
dissolution conditions. Three tablets from each product were tested each time under
varying dissolution conditions consisting of three different dissolution media, namely,
three aqueous solutions of 0.5% w/v of Sodium Lauryl Sulfate (i.e., "SLS") dissolved in
Phosphate Buffer pH 7.0, Purified Water or Acetate Buffer pH 4.5, and two different
dissolution medium volumes, namely, 500 or 900 mL per dissolution vessel (containing
one tablet per vessel) which were maintained at 37oC and agitated using paddles rotating
at either 35 or 50 rotations per minute (rpm).
During each dissolution test, one tablet of each product under evaluation was
placed in a dissolution vessel containing a certain volume (500 or 900 mL) of one of the
three dissolution media, maintained at 37oC and agitated at a certain paddle speed (35 or
50 rpm). A total of three tablets from each product were tested at each dissolution
condition. After starting the dissolution test, 5 mL samples of the dissolution medium
were withdrawn at 5, 10, 20, 30 and 45 minutes of the dissolution process, filtered and
analyzed for their drug content using High Pressure Liquid Chromatography (HPLC).
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The drug content of each sample point for the three tablets of each product tested was
then treated statistically to yield the Average and Standard Deviation (N=3) of the
Cumulative Percent Drug Dissolved from each product at each dissolution time point.
Such dissolution results, which are tabulated in Tables 1-12, were then plotted versus
time for the three products compared in this work to obtain their dissolution profiles
shown in Figures 9-20.
In addition, the 10-min, 20-min and 30-min Drug Dissolution Rates of each
product at each dissolution condition used were calculated by converting each Average of
Cumulative Percent Drug Dissolved (shown in Tables 1-12) to milligrams (mg) of Drug
Dissolved by multiplying the percent ratio (e.g., 0.65 for 65% of Cumulative Percent
Drug Dissolved) with 80 mg (i.e., the strength of each product tested), and then by
dividing such multiplication product by 10, 20 or 30 minutes, respectively, to yield the
Average 10-min, 20-min or 30-min Drug Dissolution Rates (in mg/min), respectively, for
each product tested at each dissolution condition. Similar treatment was also applied to
the corresponding Standard Deviations (also shown in Tables 1-12) to obtain the relevant,
corresponding Standard Deviations of the 10-min, 20-min or 30-min Drug Dissolution
Rates (in mg/min) for each product tested at each dissolution condition. Such Averages
and Standard Deviations of the 10-min, 20-min and 30-min Drug Dissolution Rates of
each product tested at each dissolution condition are tabulated in Tables 13-30 and
plotted as bar graphs in Figures 21-38.
Finally, the differences between the 10-min, 20-min and 30-min Drug Dissolution
Rates observed from the Brand Zocor Simvastatin 80 mg Tablets and the Generic Teva or
Dr. Reddy's Simvastatin products tested in 500 or 900 mL volumes of dissolution media
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under the different dissolution conditions used, were analyzed for statistical significance
using hypothesis t-testing wherein the t-statistics pertaining to paired comparisons of the
dissolution rates exhibited by Zocor vs. Teva and Zocor vs. Dr. Reddy's, were calculated
and compared to two-sided t-distributions with 4 degrees of freedom (i.e., 4 d.f.) for
statistical significance at P-levels smaller than 5% (i.e., P<0.05) and/or 1% (i.e., P<0.01).
Such statistical analysis and comparison results are shown in Tables 31-42 and further
summarized in Tables 43-45.
Materials
The following materials were purchased and donated for the needs of this project
by Sigmapharm Laboratories, LLC, and they were used as received:
1. Zocor (Simvastatin Tablets, USP 80 mg) of Lot No. G004118) manufactured by
Merck Pharmaceutical Company (reference branded product);
2. Simvastatin Tablets, USP 80 mg, of Lot No. 25S032 manufactured by Teva
Pharmaceuticals, Inc., as the generic equivalent of the brand Zocor;
3. Simvastatin Tablets, USP 80 mg, of Lot No. C105447 manufactured by Dr. Reddy’s
Laboratories, Ltd., as the generic equivalent of the brand Zocor;
4. Simvastatin USP Standard, of Lot No. I1H070 manufactured by USP, Rockville,
MD;
5. Sodium Lauryl Sulfate (SLS) of Lot No. S6371050141 manufactured by Merck,
Germany;
6. Phosphoric Acid 85% of Lot No. 45315604 manufactured by EMD Chemicals, NJ;
7. Sodium Phosphate of Lot No. Lot No. 46789120 manufactured by EMD Chemicals,
NJ;

	
  

23	
  
8. Monobasic Sodium Phosphate Lot No. A01131014 manufactured by EMD
Chemicals, NJ;
9. Acetic Acid of Lot No. C32004 manufactured by Mallinckrodt Chemicals;

10. Sodium Acetate of Lot No. 93454 manufactured by BDH;
11. Sodium Hydroxide of Lot No. B0630569135 manufactured by EMD Chemicals, NJ;
12. Acetonitrile of Lot No. 52040 manufactured by EMD Chemicals, NJ;
13. Whatman disc filters of 0.45 µm of Lot No. 51580 manufactured by Whatman;
14. Thermo Scientific Column, part # 30105-254630, 250 x 4.5 mm, 5 µ packing of Lot
No. 11444 manufactured by Thermo Scientific; and
15. Purified Water and HPLC-grade Water (produced at Sigmapharm Laboratories).

Methods

Dissolution Testing
Three commercial products of Simvastatin USP 80 mg Tablets, namely, the brand
Zocor reference product and two FDA-approved generic products, i.e., Teva and Reddy's,
were tested for their drug dissolution profiles using twelve different conditions. All
dissolution tests were performed using a United States Pharmacopeia apparatus II (paddle
method) dissolution bath containing six vessels maintained at 37°C. Three tablets from
each product were tested each time under varying dissolution conditions consisting of
three different dissolution media, namely, three aqueous solutions of 0.5% w/v of SLS in
Phosphate Buffer pH 7.0, Purified Water or Acetate Buffer pH 4.5, and two different
dissolution medium volumes, namely, 500 or 900 mL per dissolution vessel (containing
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one tablet per vessel), which were maintained at 37oC and agitated using paddles rotating
at either 35 or 50 rpm.

Preparation of Dissolution Media
Each dissolution medium intended for a given dissolution test was made and used
daily. A 1,000 mL volumetric cylinder was used to measure 6,000 mL of Purified Water
that was added to a large glass vessel. A stirrer was placed in the glass vessel in order to
mix the components thoroughly. The glass vessel containing the Purified Water was
placed on top of a stir plate and stirred until everything that was added became fully
dissolved.

Depending on the dissolution test planned to be performed, one of the

following dissolution media was prepared and used daily:
1. Phosphate Buffer pH 7.0 with 0.5% w/v SLS, which is the dissolution medium
recommended by USP for Simvastatin immediate release tablets (USP medium);
2. Purified Water with 0.5% w/v SLS; and
3. Acetate Buffer pH 4.5 with 0.5% w/v SLS.
If necessary, the USP medium’s pH was adjusted with Sodium Hydroxide, and
the Acetate Buffer’s pH was adjusted with Phosphoric Acid. For every liter of total
dissolution medium, 5 grams of SLS was used to make each of the dissolution media
containing 0.5% w/v SLS. It should be noted that % w/v means grams of solute (e.g., 0.5
grams of SLS) per 100 mL of solution (e.g., consisting, in this case, of SLS as the solute
and Phosphate Buffer pH 7.0, Purified Water or Acetate Buffer pH 4.5, as the solvent).
The USP medium was made up of pH 7.0 Phosphate Buffer solution containing
0.5% w/v SLS in 0.01 M Sodium Phosphate prepared by dissolving 30 grams of SLS and
8.28 grams of Monobasic Sodium Phosphate in 6,000 mL of Purified Water, and

	
  

25	
  

adjusting with 50% w/v of Sodium Hydroxide solution to a pH of 7.0. The second
dissolution medium was made up of 0.5% w/v SLS in Purified Water.

In other words,

for each liter of the second dissolution medium, Purified Water was added to 5 grams of
SLS to prepare a total volume of solution equal to 1,000 mL. Lastly, the 0.5% w/v SLS
in Acetate Buffer pH 4.5 dissolution medium was made up of 17.99 grams of Sodium
Acetate mixed with 84 mL of 2 N Acetic Acid for every 6,000 mL made containing 30
grams of SLS. It should be also noted that for the USP and Acetate Buffer dissolution
media, the pHs of the buffer solutions were always measured prior to the addition of SLS.

Dissolution Procedure
During each dissolution test, one tablet of each product under evaluation was
placed in one dissolution vessel containing a certain volume (500 or 900 mL) of one of
the three dissolution media, maintained at 37oC and agitated at a certain paddle speed (35
or 50 rpm). A total of three tablets from each product were tested at each dissolution
condition. After starting the dissolution test, 5 mL samples of the dissolution medium
were withdrawn at 5, 10, 20, 30 and 45 minutes of the dissolution process, filtered
through a Whatman disc filter of 0.45 mm and analyzed for their drug content using High
Pressure Liquid Chromatography or, as commonly referred to, HPLC analysis. After
each sample withdrawal, 5 mL of fresh dissolution medium was added (replaced) in each
dissolution vessel in order to maintain the volume of the dissolution medium constant in
each vessel. The drug content of each sample point for the three tablets of each product
tested was then treated statistically to yield the Average and Standard Deviation (N=3) of
Cumulative Percent Drug Dissolved from each product at each dissolution time point.
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Such dissolution results, which are tabulated in Tables 1-12, were then plotted versus
time for the three products compared in this work to obtain their dissolution profiles
shown in Figures 9-20. It should be also noted that after collection of the 30-minute
samples, the agitation speed of the dissolution apparatus was increased to 200 rpm for an
additional 15 minutes in order to ensure that all drug available or able to be dissolved at
the selected type and volume of dissolution medium was indeed fully dissolved at the end
of each dissolution test. Such 45-minute sample collection is also known as Recovery
Point and is listed in the last row of Tables 1-12. However, such 45-minute-recoveries
are not included in the dissolution profiles plotted in Figures 9-20, since they do not
represent actual points of drug dissolution observed under the same agitation speed
conditions used for the preceding sample collection points.

High Performance Liquid Chromatography
High performance liquid chromatography (HPLC) was used in this study for
sample analysis.

HPLC is a technique that can extensively separate a mixture of

compounds from one another and is used to identify and quantify the individual
components of the mixture (i.e., the dissolution sample in this case). HPLC distinguishes
the drug peak aside from all the other interferences from the dissolution medium and
from the array of materials used to make the tablet.
HPLC operates via a high-pressure pump to generate a particular flow rate of the
mobile phase, then an injector injects the drug sample into the continuously flowing
mobile phase that leads into the HPLC column.

The column is composed of

chromatographic packing material also known as the Stationary Phase, which is needed
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to achieve the separation, based on binding capacities to the column. Hence, the drug
peak will always come out at around the same time on the chromatogram, if not, then
something is wrong with the column, mobile phase and or HPLC conditions. Finally, a
detector detects the separated drug as it elutes from the HPLC which is wired to the
computer with Empower™ 3 Software, which was used to collect, manage and identify
the concentration of each drug sample.

Figure 8: Components of High Performance Liquid Chromatography (©2012 Waters
Corporation. Used with permission).

Preparation of Mobile Phase and HPLC System
Each time, four liters of mobile phase required for HPLC analysis was made and
used daily. The mobile phase was made up of 1,500 mL of Buffer solution of pH 4.5
containing 5.85 grams of Monobasic Sodium Phosphate and of 2,600 mL of Acetonitrile.
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This mobile phase solution was mixed and adjusted, if necessary, to a pH of 4.5 with
85% w/v of Phosphoric Acid. Once the mobile phase solution was mixed and adjusted
for its pH, it was filtered and degassed. Following the preparation of the mobile phase, a
process called Wet Prime was done to fill all the tubing lines with the mobile phase so
that there is no delay in setting up the HPLC. This process clears all the lines of the old
mobile phase used to run previous samples on other days. Also, it helps in removing any
air bubbles trapped in the lines since the lines are being flushed at a higher flow rate.
Afterwards, a process called Monitoring was done to monitor the baseline and see if there
were any unwanted peaks in order to ensure that the HPLC column and detector have
been equilibrated. Subsequently, a standard solution containing a known concentration
of Simvastatin was injected in order to ensure that Simvastatin was in fact soluble in the
dissolution medium being tested and that there was no interference to the drug peak
appearing on the chromatogram.

Preparation of Standard Simvastatin Solutions for HPLC Analysis
Prior to running a dissolution test, a standard solution of Simvastatin in the
pertinent dissolution medium was prepared for quantitation purposes.

The standard

solution was prepared by dissolving the drug in sufficient volume of methanol and then
making up the volume with the dissolution media. When preparing a standard stock
solution for a dissolution test involving 900 mL of dissolution medium volume, a 100 mL
volumetric flask was used consisting of 8.8 mg of accurately weighed Simvastatin
reference standard so that the concentration of the drug in the standard solution would
represent the 100% dissolution level expected to be obtained. This was determined by
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dividing the dosage of Simvastatin per tablet (i.e., 80 mg) by the dissolution volume (i.e.,
900 mL) present in that type of dissolution testing. On the other hand, a standard solution
for a dissolution test involving a 500 mL dissolution medium volume was prepared in a
50 mL volumetric flask consisting of 8.0 mg of accurately weighed Simvastatin reference
standard. Generally, for the Phosphate Buffer pH 7.0 with 0.5% w/v SLS and the
Purified Water with 0.5% w/v SLS dissolution media, about 5 to 10 mL of methanol was
required to dissolve Simvastatin in the flask. A standard solution made from the Acetate
Buffer pH 4.5 with 0.5% w/v SLS dissolution medium required anywhere between 20 to
40 mL of methanol to fully dissolve Simvastatin since this drug is not freely soluble in
the Acetate Buffer system.

Procedure for HPLC Analysis of Dissolution Samples
Generally, all samples were run for 20 minutes after a 10 µL injection was made
for each sample. After all dissolution samples were collected and filtered directly into
HPLC vials, they were placed in a sample tray and were each analyzed individually for
their drug content by being injected into the prepared HPLC system consisting of the
mobile phase, namely, a degassed mixture of acetonitrile and buffer solution of pH 4.5
(650:350 v/v), flowing through the HPLC column at a flow rate of 1.5 mL/min. The
HPLC column used was a Thermo Scientific Column, part # 30105-254630, 250 x 4.5
mm (lot # 11444) with 5 µ packing, which was maintained at a temperature of 45°C. The
HPLC system was also equipped with a UV detector operating at a wavelength λmax of
238 nm, which is the wavelength of maximum absorbance for Simvastatin.
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After a 10 mL injection of each filtered dissolution sample was run through the

HPLC system for a run time of 20 minutes, a chromatogram (see Figure 8a) was
produced showing the peak of the drug at about 9.5 minutes (retention time). The area of
the chromatographic Simvastatin peak produced by each dissolution sample (i.e., "sample
area") was then compared to that of the pertinent standard Simvastatin solution
representing the 100% dissolution level for the relevant dissolution test and dissolution
medium volume discussed previously ("std area"). To process the data obtained by
HPLC analysis, the factor component of the Percent Drug Dissolved formula was
calculated and entered into the Empower Software to calculate via the sample's and
standard's drug areas under the curve the actual Cumulative Percent of Drug Dissolved at
each dissolution time point.
In essence, the Cumulative Percent Drug Dissolved is equal to (sample area/Std
area) x (wt of std/stock vol) x (C/100) x (dissolution media vol/label claim) x 100. The
software calculates the sample area divided by the standard area and the factor depending
upon the dissolution medium volume was calculated by hand. The letter C in the formula
is the purity of the standard which, in this project and for the Simvastatin reference
standard used, is equal to 100%, label claim is the drug strength per tablet which is equal
to 80 mg, and the standard volume and weight varies with the volume of dissolution
medium used for the specific dissolution test.
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Figure 8a: Chromatogram of Simvastatin using this study's HPLC system (©2012
Waters Corporation. Used with permission).

Calculation of Drug Dissolution Rates
The 10-min, 20-min and 30-min Drug Dissolution Rates of each product at each
dissolution condition used were calculated by converting each Average of Cumulative
Percent Drug Dissolved (shown in Tables 1-12) to milligrams (mg) of Drug Dissolved by
multiplying the percent ratio (e.g., 0.65 for 65% of Cumulative Percent Drug Dissolved)
with 80 mg (i.e., the strength of each product tested), and then by dividing such
multiplication product by 10, 20 or 30 minutes, respectively, to yield the Average 10min, 20-min or 30-min Drug Dissolution Rates (in mg/min), respectively, for each
product tested at each dissolution condition. Similar treatment was also applied to the
corresponding Standard Deviations (also shown in Tables 1-12) to obtain the relevant,
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corresponding Standard Deviations of the 10-min, 20-min or 30-min Drug Dissolution
Rates (in mg/min) for each product tested at each dissolution condition. Such Averages
and Standard Deviations of the 10-min, 20-min and 30-min Drug Dissolution Rates of
each product tested at each dissolution condition are tabulated in Tables 13-30 and
plotted as bar graphs in Figures 21-38.
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RESULTS AND DISCUSSION

Dissolution Profiles
The results of dissolution testing conducted under twelve different conditions
(i.e., 12 combinations of three different dissolution media and two different dissolution
volumes and agitation speeds) on the three commercial Simvastatin products under
evaluation are tabulated in Tables 1-12 as Averages of Cumulative Percent Drug
Dissolved from three tablets of each product (i.e., N=3), along with their corresponding
Standard Deviations (given in parentheses), observed at each time point of dissolution
sample collection. In addition, such dissolution results are plotted versus time (minutes)
of sample collection in Figures 9-20 to display the dissolution profiles of the three tested
Simvastatin products exhibited at such twelve dissolution conditions.
It should be also noted that after collection of the 30-minute samples, the agitation
speed of the dissolution apparatus was increased to 200 rotations per minute (rpm) for an
additional 15 minutes in order to ensure that all drug available or able to be dissolved at
the selected type and volume of dissolution medium was indeed fully dissolved at the end
of each dissolution test. Such 45-minute sample collection is also known as Recovery
Point and is presented in the last row of Tables 1-12 below. However, such 45-minuterecoveries are not included in the dissolution profiles plotted in Figures 9-20, since they
do not represent actual points of drug dissolution observed under the same agitation
speed conditions used for the preceding sample collection points.
As shown in Figures 9-20, various dissolution conditions produced dissolution
profiles of the three Simvastatin products possessing varying degrees of similarities or
differences amongst them, as seen in the Discussion section below.
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Table 1: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by
paddles rotating at 35 rpm. The Averages of Cumulative-Percent-Drug-Dissolved from three tablets
of each product are reported along with their corresponding Standard Deviations (given in parentheses).

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

2% (1.5)

32% (5.2)

74% (15)

10

39% (8.9)

60% (2.5)

83% (9.8)

20

79% (6.6)

80% (2.1)

90% (6.2)

30

86% (3.1)

86% (1.0)

93% (5.0)

45 (recovery)

94% (0.6)

95% (0.0)

98% (0.6)

Figure 9: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80
mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium)
maintained at 37°C and agitated by paddles rotating at 35 rpm. (Each point is the Average of
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations)
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Table 2: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Purified Water maintained at 37°C and agitated by paddles rotating at 35 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations, which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

4% (2.0)

33% (6.6)

35% (9.6)

10

44% (9.5)

59% (1.0)

58% (5.5)

20

62% (2.6)

63% (1.5)

68% (0.0)

30

64% (2.1)

64% (1.2)

71% (3.2)

45 (recovery)

63% (1.2)

64% (0.6)

71% (1.5)

Figure 10: Dissolution Profiles of three commercial products of Simvastatin Tablets,
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated
by paddles rotating at 35 rpm. (Each point represents the Average of the Cumulative-Percent-DrugDissolved from three tablets, and error-bars represent the corresponding Standard Deviations)
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Table 3: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 35 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

6% (7.0)

35% (7.6)

23% (8.3)

10

34% (17.2)

66% (7.5)

46% (5.2)

20

69% (2.6)

75% (2.5)

60% (8.5)

30

73% (0.6)

76% (1.0)

62% (7.0)

45 (recovery)

81% (1.2)

80% (0.6)

73% (7.5)

Figure 11: Dissolution Profiles of three commercial products of Simvastatin Tablets,
USP 80 mg (Zocor, Teva and Dr. Reddy's) in 500 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37°C and agitated
by paddles rotating at 35 rpm. (Each point represents the Average of the Cumulative-Percent-DrugDissolved from three tablets, and error-bars represent the corresponding Standard Deviations)
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Table 4: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by
paddles rotating at 50 rpm. The Averages of Cumulative-Percent-Drug-Dissolved from three tablets
of each product are reported along with their corresponding Standard Deviations (given in parentheses).

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

12% (8.3)

60% (10.5)

61% (6.9)

10

64% (5.5)

86% (5.3)

86% (1.5)

20

90% (0.0)

91% (3.1)

94% (2.1)

30

93% (0.6)

92% (2.5)

95% (2.1)

45 (recovery)

95% (0.6)

94% (1.5)

96% (1.2)

Figure 12: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80
mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium)
maintained at 37°C and agitated by paddles rotating at 50 rpm. (Each point is the Average of
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations)
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Table 5: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Purified Water maintained at 37°C and agitated by paddles rotating at 50 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

24% (15.3)

50% (16.3)

47% (13.2)

10

75% (4.2)

80% (2.1)

69% (3.5)

20

83% (1.0)

84% (2.0)

72% (1.0)

30

80% (1.7)

84% (0.6)

70% (1.5)

45 (recovery)

78% (1.0)

84% (3.1)

67% (1.0)

Figure 13: Dissolution Profiles of three commercial products of Simvastatin Tablets,
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated
by paddles rotating at 50 rpm. (Each point represents the Average of the Cumulative-Percent-DrugDissolved from three tablets, and error-bars represent the corresponding Standard Deviations)
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Table 6: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 50 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

37% (1.2)

73% (4.7)

36% (13.1)

10

78% (3.2)

82% (2.6)

68% (3.0)

20

87% (0.6)

83% (1.5)

79% (0.6)

30

85% (1.0)

82% (0.6)

81% (0.0)

45 (recovery)

83% (1.5)

82% (1.0)

82% (0.6)

Figure 14: Dissolution Profiles of three commercial products of Simvastatin Tablets,
USP 80 mg (Zocor, Teva and Dr. Reddy's) in 500 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37°C and agitated
by paddles rotating at 50 rpm. (Each point represents the Average of the Cumulative-Percent-DrugDissolved from three tablets, and error-bars represent the corresponding Standard Deviations)

	
  

40	
  

Table 7: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by
paddles rotating at 35 rpm. The Averages of Cumulative-Percent-Drug-Dissolved from three tablets
of each product are reported along with their corresponding Standard Deviations (given in parentheses).

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

6% (2.0)

21% (17.0)

18% (0.6)

10

44% (19.3)

49% (15.8)

50% (9.0)

20

79% (3.0)

79% (8.7)

79% (4.2)

30

89% (1.0)

86% (5.5)

88% (1.2)

45 (recovery)

96% (0.6)

95% (0.0)

99% (1.2)

Figure 15: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80
mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium)
maintained at 37°C and agitated by paddles rotating at 35 rpm. (Each point is the Average of
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations)
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Table 8: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Purified Water maintained at 37°C and agitated by paddles rotating at 35 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

6% (3.1)

40% (1.0)

34% (3.1)

10

47% (9.6)

69% (4.7)

63% (4.7)

20

76% (2.6)

83% (2.1)

85% (4.0)

30

81% (1.5)

82% (2.0)

89% (2.0)

45 (recovery)

80% (1.0)

82% (1.0)

92% (1.0)

Figure 16: Dissolution Profiles of three commercial products of Simvastatin Tablets,
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated
by paddles rotating at 35 rpm. (Each point represents the Average of the Cumulative-Percent-DrugDissolved from three tablets, and error-bars represent the corresponding Standard Deviations)
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Table 9: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 35 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

7% (6.4)

36% (13.5)

27% (6.0)

10

34% (15.7)

58% (14.3)

55% (6.1)

20

67% (4.7)

73% (6.7)

71% (2.6)

30

73% (2.6)

74% (2.0)

76% (1.5)

45 (recovery)

77% (0.6)

77% (1.0)

81% (1.2)

Figure 17: Dissolution results obtained from three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 35 rpm.
(Each point represents the Average of the Cumulative-Percent-Drug-Dissolved from three tablets, and
error-bars represent the corresponding Standard Deviations)
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Table 10: Cumulative Percent Drug Dissolved from 3 marketed products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by
paddles rotating at 50 rpm. The Averages of Cumulative-Percent-Drug-Dissolved from three tablets
of each product are reported along with their corresponding Standard Deviations (given in parentheses).

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

9% (3.5)

62% (7.5)

53% (0.6)

10

76% (9.1)

89% (2.5)

92% (2.6)

20

95% (0.6)

98% (2.6)

100% (1.5)

30

96% (1.2)

98% (2.5)

102% (1.0)

45 (recovery)

97% (1.2)

99% (2.1)

103% (1.0)

Figure 18: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80
mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium)
maintained at 37°C and agitated by paddles rotating at 50 rpm. (Each point is the Average of
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations)
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Table 11: Cumulative Percent Drug Dissolved from 3 marketed products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Purified Water maintained at 37°C and agitated by paddles rotating at 50 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

8% (4.6)

29% (25.7)

67% (0.6)

10

55% (15.7)

78% (3.6)

97% (1.5)

20

85% (1.0)

83% (3.2)

102% (0.0)

30

85% (0.6)

89% (2.6)

101% (1.0)

45 (recovery)

86% (1.5)

87% (0.6)

101% (1.5)

Figure 19: Dissolution Profiles of three commercial products of Simvastatin Tablets,
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated
by paddles rotating at 50 rpm. (Each point represents the Average of the Cumulative-Percent-DrugDissolved from three tablets, and error-bars represent the corresponding Standard Deviations)
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Table 12: Cumulative Percent Drug Dissolved from 3 marketed products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 50 rpm.
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are
reported along with their corresponding Standard Deviations which are given in parentheses.

Time (min)

Zocor Tablets
(G004118)

Teva Tablets
(25S032)

Dr. Reddy's Tablets
(C105447)

0

0%

0%

0%

5

11% (7.8)

50% (10.5)

55% (2.6)

10

69% (4.6)

75% (1.5)

76% (1.2)

20

80% (1.5)

79% (1.0)

83% (2.1)

30

78% (0.0)

77% (1.0)

82% (1.0)

45 (recovery)

76% (0.0)

76% (1.0)

82% (1.2)

Figure 20: Dissolution results obtained from three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot#
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 50 rpm.
(Each point represents the Average of the Cumulative-Percent-Drug-Dissolved from three tablets, and
error-bars represent the corresponding Standard Deviations)
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Dissolution Rates
The 10-min, 20-min and 30-min drug dissolution rates observed from the three
commercial Simvastatin products tested in 500 or 900 mL volumes of dissolution media
under the different dissolution conditions used, are tabulated in Tables 13-30 as Averages
of Cumulative Amount Drug Dissolved per Minute (in mg/min) from three tablets of
each product (i.e., N=3), along with their corresponding Standard Deviations (given in
parentheses), within the first 10, 20 and 30 minutes, respectively, of the dissolution
process. Such drug dissolution rates are calculated from the Averages of Cumulative
Percent Drug Dissolved at the relevant time points, i.e., at 10, 20 or 30 minutes of
dissolution (listed previously in Tables 1-12), by dividing such averages (expressed in %)
by 100, then multiplying the results by 80 mg and then dividing the products by 10, 20 or
30 minutes, respectively, to find the 10-min, 20-min or 30-min drug dissolution rates,
respectively, in mg/min. Similar treatment of the corresponding Standard Deviation
percents of drug dissolved reported also for the same time points in Tables 1-12, yield the
Standard Deviations of such drug dissolution rates which are also listed in Tables 13-30.
In addition, such 10-min, 20-min and 30-min drug dissolution rates observed from
each of the three commercial Simvastatin products tested in 500 mL or 900 mL volumes
of pertinent dissolution medium and agitation speed, are also compared in the bar graphs
of Figures 21-38. As shown in Figures 21-38 and well in agreement with comparisons of
the dissolution profiles previously shown in Figures 9-20, various dissolution conditions
resulted in 10-min, 20-min and 30-min drug dissolution rates of the three commercial
Simvastatin products possessing varying degrees of similarities or differences amongst
them, which are further compared and explained in the Discussion section below.
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Table 13: Drug Dissolution Rates displayed by three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations which are given in parentheses.

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

3.12 (0.71)

4.80 (0.20)

6.64 (0.78)

900 mL

3.52 (1.54)

3.92 (1.26)

4.00 (0.72)

Figure 21: Drug Dissolution Rates displayed by 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 35 rpm.
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Table 14: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained
at 37oC and agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

3.52 (0.76)

4.72 (0.08)

4.64 (0.44)

900 mL

3.76 (0.77)

5.52 (0.38)

5.04 (0.38)

Figure 22: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by
paddles rotating at 35 rpm.
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Table 15: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5
maintained at 37oC and agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.72 (1.38)

5.28 (0.60)

3.68 (0.42)

900 mL

2.72 (1.26)

4.64 (1.14)

4.40 (0.49)

Figure 23: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 10-Minutes of
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles
rotating at 35 rpm.
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Table 16: Drug Dissolution Rates displayed by three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations which are given in parentheses.

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

5.12 (0.44)

6.88 (0.42)

6.88 (0.12)

900 mL

6.08 (0.73)

7.12 (0.20)

7.36 (0.21)

Figure 24: Drug Dissolution Rates displayed by 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 50 rpm.
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Table 17: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained
at 37oC and agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

6.00 (0.34)

6.40 (0.17)

5.52 (0.28)

900 mL

4.40 (1.26)

6.24 (0.29)

7.76 (0.12)

Figure 25: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by
paddles rotating at 50 rpm.
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Table 18: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5
maintained at 37oC and agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

6.24 (0.26)

6.56 (0.21)

5.44 (0.24)

900 mL

5.52 (0.37)

6.00 (0.12)

6.08 (0.10)

Figure 26: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 10-Minutes of
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles
rotating at 50 rpm.
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Table 19: Drug Dissolution Rates displayed by three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations which are given in parentheses.

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

3.16 (0.26)

3.20 (0.08)

3.60 (0.25)

900 mL

3.16 (0.12)

3.16 (0.35)

3.16 (0.17)

Figure 27: Drug Dissolution Rates displayed by 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 35 rpm.
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Table 20: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained
at 37oC and agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.48 (0.10)

2.52 (0.06)

2.72 (0.00)

900 mL

3.04 (0.10)

3.32 (0.08)

3.40 (0.16)

Figure 28: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by
paddles rotating at 35 rpm.
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Table 21: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5
maintained at 37oC and agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.76 (0.10)

3.00 (0.10)

2.40 (0.34)

900 mL

2.68 (0.19)

2.92 (0.27)

2.84 (0.10)

Figure 29: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 20-Minutes of
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles
rotating at 35 rpm.
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Table 22: Drug Dissolution Rates displayed by three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations which are given in parentheses.

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

3.60 (0.00)

3.64 (0.12)

3.76 (0.08)

900 mL

3.80 (0.02)

3.92 (0.10)

4.00 (0.06)

Figure 30: Drug Dissolution Rates displayed by 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 50 rpm.
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Table 23: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained
at 37oC and agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

3.32 (0.04)

3.36 (0.08)

2.88 (0.04)

900 mL

3.40 (0.04)

3.32 (0.13)

4.08 (0.00)

Figure 31: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by
paddles rotating at 50 rpm.
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Table 24: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5
maintained at 37oC and agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

3.16 (0.02)

3.20 (0.06)

3.60 (0.02)

900 mL

3.20 (0.06)

2.68 (0.04)

3.32 (0.08)

Figure 32: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 20-Minutes of
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles
rotating at 50 rpm.
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Table 25: Drug Dissolution Rates displayed by three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations which are given in parentheses.

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.29 (0.08)

2.29 (0.03)

2.48 (0.13)

900 mL

2.37 (0.03)

2.29 (0.15)

2.35 (0.03)

Figure 33: Drug Dissolution Rates displayed by 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 35 rpm.
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Table 26: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained
at 37oC and agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

1.71 (0.06)

1.71 (0.03)

1.89 (0.09)

900 mL

2.16 (0.04)

2.19 (0.05)

2.37 (0.05)

Figure 34: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by
paddles rotating at 35 rpm.
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Table 27: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5
maintained at 37oC and agitated by paddles rotating at 35 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

1.95 (0.02)

2.03 (0.27)

1.65 (0.19)

900 mL

1.95 (0.07)

1.97 (0.05)

2.03 (0.04)

Figure 35: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 30-Minutes of
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles
rotating at 35 rpm.
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Table 28: Drug Dissolution Rates displayed by three commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations which are given in parentheses.

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.28 (0.02)

2.45 (0.07)

2.53 (0.06)

900 mL

2.56 (0.03)

2.61 (0.07)

2.72 (0.03)

Figure 36: Drug Dissolution Rates displayed by 3 commercial products of Simvastatin
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and
agitated by paddles rotating at 50 rpm.
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Table 29: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained
at 37oC and agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.13 (0.05)

2.24 (0.02)

1.87 (0.04)

900 mL

2.26 (0.02)

2.37 (0.07)

2.69 (0.27)

Figure 37: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by
paddles rotating at 50 rpm.
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Table 30: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy'slot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5
maintained at 37oC and agitated by paddles rotating at 50 rpm.
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along
with their corresponding Standard Deviations (given in parentheses).

Volume of
Dissolution
Medium

Zocor Tablets
(G004118)
mg/min

Teva
(25S032)
mg/min

Dr. Reddy's
(C105447)
mg/min

500 mL

2.26 (0.03)

2.18 (0.02)

2.16 (0.00)

900 mL

2.08 (0.00)

2.05 (0.03)

2.19 (0.03)

Figure 38: Drug Dissolution Rates (mg/min) displayed by three commercial products of
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 30-Minutes of
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles
rotating at 50 rpm.
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Statistical Analysis
The differences between the 10-min, 20-min and 30-min Drug Dissolution Rates

observed from the Brand Zocor Simvastatin 80 mg Tablets and the Generic Teva or Dr.
Reddy's Simvastatin products tested in 500 or 900 mL volumes of dissolution media
under the different dissolution conditions used, were analyzed for statistical significance
using hypothesis t-testing wherein the t-statistics pertaining to paired comparisons of the
dissolution rates exhibited by the Zocor vs. Teva and Zocor vs. Dr. Reddy's productcomparisons, were calculated and compared to two-sided t-distributions with 4 degrees of
freedom (i.e., 4 d.f.) for statistical significance at P-levels smaller than 5% (i.e., P<0.05)
and/or 1% (i.e., P<0.01). Such statistical analysis and comparison results are shown in
Tables 31-42 and summarized in Tables 43-45.
Specifically, a hypothesis t-testing for Two-Independent-Groups-with-UnknownVariance (Bolton 2004, p. 150) was conducted for each drug dissolution rate observed at
each dissolution condition by, and between, the brand Zocor product (reference product
P1) and the generic Teva, or the other generic Dr. Reddy's, products (test products - each
one P2). Initially, the Pooled Variance (Sp2) of the compared drug dissolution rate values
was calculated using their Standard Deviations (i.e., S1 and S2) and sample sizes (i.e.,
N1=3 and N2=3), as follows:
Sp 2

(N1 - 1) S12 + (N2 - 1) S22
= ------------------------------------N1 + N2 - 2

After calculating the Pooled Variance (Sp2) and, therefore, estimating the Pooled
Standard Deviation (Sp which is the square root of Sp2), the corresponding t-statistics (t)
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were calculated using the means (m1 and m2) of the compared drug dissolution rate
values displayed by the two products, as follows:
| m1 - m2 |
t = -----------------------------Sp (1/N1 + 1/N2)1/2
Such t-statistics from each comparison were then evaluated for their statistical
significance against the corresponding values for statistical significance with 4 degrees of
freedom (d.f.) at the two-sided t-distribution P-levels of 5% (for P<0.05 when t>t0.95, i.e.,
t>2.78 for 4 d.f.) and/or 1% (for P<0.01 when t>t0.99, i.e., t>4.60 for 4 d.f.), as shown in
Tables 31-42 and further summarized in Tables 43-45.
The results, along with the corresponding declarations for statistical significance
in the differences between the drug dissolution rates displayed by the two compared
products are tabulated in Tables 31-42. P-values smaller than 0.05, or even better, Pvalues smaller than 0.01, indicate statistically significant differences between the drug
dissolution rates of each pair of compared products.
The statistical findings tabulated in Tables 31-42 are compared and further
explained in the Discussion section below.
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Table 31: Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 35 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
500 mL
35 rpm

10-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

3.12
(0.71)

4.80
(0.20)

Purified
Water
with
0.5% w/v
of SLS

3.52
(0.76)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

3.12
(0.71)

2.72
(1.38)

tstatistic

Statistically
Significant
Difference
YES

3.95
6.64
(0.78)

4.72
(0.08)

3.52
(0.76)

2.72
(1.38)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

5.78

2.72

t > t0.95
YES

Significant
Difference

t > t0.99

(t > 4.60)

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95

t < t0.95

(t < 2.78)
YES

5.28
(0.60)

2.95

3.68
(0.42)

1.15

Significant
Difference

P < 0.05

NO

2.21

of
Significance

(t > 2.78)

(t < 2.78)
4.64
(0.44)

P-level

t > t0.95

Insignificant
Difference at
the 5% level
Significant
Difference

(t > 2.78)

P < 0.05

NO

Insignificant
Difference at
the 5% level

t < t0.95
(t < 2.78)
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Table 32: Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 35 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
900 mL
35 rpm

10-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

3.52
(1.54)

3.92
(1.26)

Purified
Water
with
0.5% w/v
of SLS

3.76
(0.77)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

3.52
(1.54)

2.72
(1.26)

tstatistic

Statistically
Significant
Difference
NO

0.35

t < t0.95
(t < 2.78)

4.00
(0.72)

NO

0.49

t < t0.95
(t < 2.78)
YES

5.52
(0.38)

3.76
(0.77)

2.72
(1.26)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

3.55

5.04
(0.38)

2.58

t > t0.95

Significant
Difference
Insignificant
Difference at
the 5% level

t < t0.95
NO

2.15

Insignificant
Difference at
the 5% level

NO

t < t0.95

(t < 2.78)
4.40
(0.49)

Insignificant
Difference at
the 5% level

P < 0.05

(t < 2.78)

1.96

of
Significance

(t > 2.78)

NO

4.64
(1.14)

P-level

t < t0.95

(t < 2.78)

Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level

	
  

69	
  

Table 33: Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 50 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
500 mL
50 rpm

10-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

5.12
(0.44)

6.88
(0.42)

Purified
Water
with
0.5% w/v
of SLS

6.00
(0.34)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

5.12
(0.44)

6.24
(0.26)

tstatistic

Statistically
Significant
Difference
YES

5.01
6.88
(0.12)

6.40
(0.17)

6.00
(0.34)

6.24
(0.26)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

6.68

1.82

t > t0.99
YES

Significant
Difference

t > t0.99
(t > 4.60)

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95

t < t0.95
(t < 2.78)
NO

6.56
(0.21)

1.66

t < t0.95

(t < 2.78)
5.44
(0.24)

YES

3.92

Significant
Difference

P < 0.01

NO

1.89

of
Significance

(t > 4.60)

(t < 2.78)
5.52
(0.28)

P-level

t > t0.95

(t > 2.78)

Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Significant
Difference

P < 0.05
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Table 34: Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 50 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
900 mL
50 rpm

10-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

6.08
(0.73)

7.12
(0.20)

Purified
Water
with
0.5% w/v
of SLS

4.40
(1.26)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

6.08
(0.73)

5.52
(0.37)

tstatistic

Statistically
Significant
Difference
NO

2.38

t < t0.95
(t < 2.78)

7.36
(0.21)

6.24
(0.29)

4.40
(1.26)

5.52
(0.37)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

YES

2.92

2.47

t > t0.95

6.00
(0.12)

2.14

Insignificant
Difference at
the 5% level

t = t0.99

Significant
Difference

(t = 4.60)

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95
NO

2.53

Significant
Difference

NO

t < t0.95

(t < 2.78)
6.08
(0.10)

Insignificant
Difference at
the 5% level

P < 0.05

YES

4.60

of
Significance

(t > 2.78)

(t < 2.78)
7.76
(0.12)

P-level

t < t0.95

(t < 2.78)

Insignificant
Difference at
the 5% level
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Table 35: Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 35 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
500 mL
35 rpm

20-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

3.16
(0.26)

3.20
(0.08)

Purified
Water
with
0.5% w/v
of SLS

2.48
(0.10)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

3.16
(0.26)

2.76
(0.10)

tstatistic

Statistically
Significant
Difference
NO

0.26

t < t0.95
(t < 2.78)

3.60
(0.25)

NO

2.11

t < t0.95
(t < 2.78)
NO

2.52
(0.06)

2.48
(0.10)

2.76
(0.10)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

0.59

t < t0.95
(t < 2.78)

2.72
(0.00)

3.00
(0.10)

YES

4.16

2.94

2.40
(0.34)

1.76

t > t0.95

P-level
of
Significance
Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Significant
Difference

(t > 2.78)

P < 0.05

YES

Significant
Difference

t > t0.95

(t > 2.78)

P < 0.05

NO

Insignificant
Difference at
the 5% level

t < t0.95

(t < 2.78)

	
  

72	
  

Table 36: Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 35 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
900 mL
35 rpm

20-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

3.16
(0.12)

3.16
(0.35)

Purified
Water
with
0.5% w/v
of SLS

3.04
(0.10)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

3.16
(0.12)

2.68
(0.19)

tstatistic

Statistically
Significant
Difference
NO

0

t < t0.95
(t < 2.78)

3.16
(0.17)

NO

0

t < t0.95
(t < 2.78)
YES

3.32
(0.08)

3.04
(0.10)

2.68
(0.19)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

3.79

3.40
(0.16)

2.92
(0.27)

3.31

1.26

t > t0.95

Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Significant
Difference

P < 0.05

YES

Significant
Difference

t > t0.95
(t > 2.78)

P < 0.05

NO

Insignificant
Difference at
the 5% level

t < t0.95
NO

1.29

of
Significance

(t > 2.78)

(t < 2.78)
2.84
(0.10)

P-level

t < t0.95

(t < 2.78)

Insignificant
Difference at
the 5% level
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Table 37: Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 50 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
500 mL
50 rpm

20-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

3.60
(0.00)

3.64
(0.12)

Purified
Water
with
0.5% w/v
of SLS

3.32
(0.04)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

3.60
(0.00)

3.16
(0.02)

tstatistic

Statistically
Significant
Difference
NO

0.58

t < t0.95
(t < 2.78)

3.76
(0.08)

3.36
(0.08)

3.32
(0.04)

3.16
(0.02)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

YES

3.46

0.78

t > t0.95

3.20
(0.06)

1.10

Insignificant
Difference at
the 5% level

t > t0.99

Significant
Difference

(t > 4.60)

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95
YES

26.94

Significant
Difference

NO

t < t0.95

(t < 2.78)
3.60
(0.02)

Insignificant
Difference at
the 5% level

P < 0.05

YES

13.47

of
Significance

(t > 2.78)

(t < 2.78)
2.88
(0.04)

P-level

t > t0.99

(t > 4.60)

Significant
Difference

P < 0.01
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Table 38: Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 50 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
900 mL
50 rpm

20-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

3.80
(0.02)

3.92
(0.10)

Purified
Water
with
0.5% w/v
of SLS

3.40
(0.04)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

3.80
(0.02)

3.20
(0.06)

tstatistic

Statistically
Significant
Difference
NO

2.04

t < t0.95
(t < 2.78)

4.00
(0.06)

3.32
(0.13)

3.40
(0.04)

3.20
(0.06)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

YES

5.48

1.02

t > t0.99

2.68
(0.04)

12.49

3.32
(0.08)

2.08

Insignificant
Difference at
the 5% level
Significant
Difference

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95
YES

29.45

of
Significance

(t > 4.60)

(t < 2.78)
4.08
(0.00)

P-level

t > t0.99

Significant
Difference

(t > 4.60)

P < 0.01

YES

Significant
Difference

t > t0.99

(t > 4.60)

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95

(t < 2.78)
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Table 39: Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 35 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
500 mL
35 rpm

30-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

2.29
(0.08)

2.29
(0.08)

Purified
Water
with
0.5% w/v
of SLS

1.71
(0.06)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

2.29
(0.08)

1.95
(0.02)

tstatistic

Statistically
Significant
Difference
NO

0

t < t0.95
(t < 2.78)

2.48
(0.13)

NO

2.16

t < t0.95
(t < 2.78)
NO

1.71
(0.03)

1.71
(0.06)

1.95
(0.02)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

0

t < t0.95
(t < 2.78)

1.89
(0.09)

2.03
(0.27)

YES

2.88

0.51

t > t0.95

Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Significant
Difference

P < 0.05

NO

Insignificant
Difference at
the 5% level

t < t0.95
NO

2.72

of
Significance

(t > 2.78)

(t < 2.78)
1.65
(0.19)

P-level

t < t0.95

(t < 2.78)

Insignificant
Difference at
the 5% level
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Table 40: Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 35 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
900 mL
35 rpm

30-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

2.37
(0.03)

2.29
(0.15)

Purified
Water
with
0.5% w/v
of SLS

2.16
(0.04)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

2.37
(0.03)

1.95
(0.07)

tstatistic

Statistically
Significant
Difference
NO

0.91

t < t0.95
(t < 2.78)

2.35
(0.03)

NO

0.82

t < t0.95
(t < 2.78)
NO

2.19
(0.05)

2.16
(0.04)

1.95
(0.07)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

0.81

t < t0.95
(t < 2.78)

2.37
(0.05)

1.97
(0.05)

YES

5.68

0.4

t > t0.99

Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Significant
Difference

P < 0.01

NO

Insignificant
Difference at
the 5% level

t < t0.95
NO

1.72

of
Significance

(t > 4.60)

(t < 2.78)
2.03
(0.04)

P-level

t < t0.95

(t < 2.78)

Insignificant
Difference at
the 5% level

	
  

77	
  

Table 41: Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 50 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
500 mL
50 rpm

30-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

2.28
(0.02)

2.45
(0.07)

Purified
Water
with
0.5% w/v
of SLS

2.13
(0.05)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

2.28
(0.02)

2.26
(0.03)

tstatistic

Statistically
Significant
Difference
YES

4.05
2.53
(0.06)

2.24
(0.02)

2.13
(0.05)

2.26
(0.03)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

6.85

3.54

1.87
(0.04)

2.18
(0.02)

7.03

3.84

2.26
(0.00)

0

t > t0.95

P-level
of
Significance
Significant
Difference

(t > 2.78)

P < 0.05

YES

Significant
Difference

t > t0.99
(t > 4.60)

P < 0.01

YES

Significant
Difference

t > t0.95
(t > 2.78)

P < 0.05

YES

Significant
Difference

t > t0.99
(t > 4.60)

P < 0.01

YES

Significant
Difference

t > t0.95

(t > 2.78)

P < 0.05

NO

Insignificant
Difference at
the 5% level

t < t0.95

(t < 2.78)
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Table 42: Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 50 rpm
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their
corresponding Standard Deviations (S1 and S2) which are given in parentheses.

Statistical
Table

Dissolution
Medium
900 mL
50 rpm

30-min Drug Dissolution Rate
(mg/min)
Zocor
m1
(S1)

Teva
m2
(S2)

Phosphate
Buffer
pH 7.0
with 0.5%
w/v of SLS

2.56
(0.03)

2.61
(0.07)

Purified
Water
with
0.5% w/v
of SLS

2.26
(0.02)

Acetate
Buffer
pH 4.5
with 0.5%
w/v of SLS

2.56
(0.03)

2.08
(0.00)

tstatistic

Statistically
Significant
Difference
NO

1.14

t < t0.95
(t < 2.78)

2.72
(0.03)

2.37
(0.07)

2.26
(0.02)

2.08
(0.00)

Reddy’s
m2
(S2)

Evaluation of the Statistical
Significance of the Difference
Between the Brand and Generic

YES

6.53

2.62

t > t0.99

Insignificant
Difference at
the 5% level

t < t0.95
(t < 2.78)

1.73

t < t0.95

(t < 2.78)
2.19
(0.03)

YES

6.35

Significant
Difference

NO

t < t0.95

NO

2.05
(0.03)

Insignificant
Difference at
the 5% level

P < 0.01

NO

2.75

of
Significance

(t > 4.60)

(t < 2.78)
2.69
(0.27)

P-level

t > t0.99

(t > 4.60)

Insignificant
Difference at
the 5% level
Insignificant
Difference at
the 5% level
Significant
Difference

P < 0.01
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Further Statistical Tabulations
In order to evaluate more easily and compare the findings of the various statistical
hypothesis t-testing conducted in this study, all statistical comparisons of the dissolution
rates observed at the different dissolution conditions used, namely, dissolution volumes
of 500 mL and 900 mL and agitation speeds of 35 rpm and 50 rpm, for each dissolution
medium used, namely, aqueous solutions of 0.5% w/v SLS in Phosphate Buffer pH 7.0,
Purified Water, and Acetate Buffer pH 4.5, respectively, are summarized and compared
again in Tables 43-45, respectively, wherein P-levels smaller than 5% (i.e., P<0.05) are
considered sufficient to declare a statistically significant difference between the 10-min,
20-min or 30-min drug dissolution rates of each pair of products tested. In addition,
whenever the calculated t-statistic values (previously tabulated in Tables 31-42) were
sufficient to declare statistically significant differences between the drug dissolution rates
of the tested product-pairs at a P-level smaller than 1% (i.e., P<0.01), such level of
statistical significance is also reported in Tables 43-45 below.
It should be noted that differences between dissolution rates at P<0.01 are
statistically more significant than those declared at P<0.05. In essence, when a difference
between the dissolution rates of two products is declared as being statistically significant
at P<0.05, this means that there is not more than 5% probability for such declaration of
statistical significance to be actually wrong. Therefore, a declaration of significance at
P<0.01 whereas, now, there is not more than 1% chance for such declaration to be wrong,
increases the certainty of the conclusion that the compared dissolution rates are different.
The statistical findings summarized in Tables 43-45 are further compared and
more elaborated in the Discussion section below.

	
  

80	
  

Table 43: Statistical Comparison of the Drug Dissolution Rates displayed by Branded
(Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg, in two
different dissolution volumes (per vessel) of an aqueous medium consisting of 0.5% w/v
SLS in Phosphate Buffer pH 7.0 agitated by paddles rotating at two different speeds.
A P-value smaller than 0.05 indicates statistically significant difference between the drug dissolution rates
of the compared products, whereas P-values greater than 0.05 indicate statistical similarity of the rates.

Dissolution Conditions
(Phosphate Buffer pH 7.0 with 0.5% w/v SLS)

Statistically Significant Difference
Between the Brand and Generic

Drug
Dissolution
Rate

Zocor (Brand)
vs.
Teva (Generic)

Dissolution
Volume (mL)

Agitation
Speed (rpm)
35 rpm

500 mL

10-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm
35 rpm
500 mL

20-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm
35 rpm
500 mL

30-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm

Zocor (Brand)
vs.
Reddy’s (Generic)

YES

YES

P < 0.05

P < 0.01

YES

YES

P < 0.05

P < 0.05

NO

NO

P > 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.05

NO

NO

P > 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.05

NO

NO

P > 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.01

NO

NO

P > 0.05

P > 0.05

YES

YES

P < 0.05

P < 0.01

NO

NO

P > 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.01
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Table 44: Statistical Comparison of the Drug Dissolution Rates displayed by Branded
(Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg, in two
different dissolution volumes (per vessel) of an aqueous medium consisting of 0.5% w/v
SLS in Purified Water agitated by paddles rotating at two different speeds.
A P-value smaller than 0.05 indicates statistically significant difference between the drug dissolution rates
of the compared products, whereas P-values greater than 0.05 indicate statistical similarity of the rates.

Dissolution Conditions
(Purified Water with 0.5% w/v SLS)
Drug
Dissolution
Rate

Dissolution
Volume (mL)

Agitation
Speed (rpm)
35 rpm

500 mL

10-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm
35 rpm
500 mL

20-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm
35 rpm
500 mL

30-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm

Statistically Significant Difference
Between the Brand and Generic
Zocor (Brand)
vs.
Teva (Generic)

Zocor (Brand)
vs.
Reddy’s (Generic)

NO

NO

P > 0.05

P > 0.05

NO

NO

P > 0.05

P > 0.05

YES

NO

P < 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.05

NO

YES

P > 0.05

P < 0.05

NO

YES

P > 0.05

P < 0.01

YES

YES

P < 0.05

P < 0.05

NO

YES

P > 0.05

P < 0.01

NO

YES

P > 0.05

P < 0.05

YES

YES

P < 0.05

P < 0.01

NO

YES

P > 0.05

P < 0.01

NO

NO

P > 0.05

P > 0.05
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Table 45: Statistical Comparison of the Drug Dissolution Rates displayed by Branded
(Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg, in two
different dissolution volumes (per vessel) of an aqueous medium consisting of 0.5% w/v
SLS in Acetate Buffer pH 4.5 agitated by paddles rotating at two different speeds.
A P-value smaller than 0.05 indicates statistically significant difference between the drug dissolution rates
of the compared products, whereas P-values greater than 0.05 indicate statistical similarity of the rates.

Dissolution Conditions
(Acetate Buffer pH 4.5 with 0.5% w/v SLS)
Drug
Dissolution
Rate

Dissolution
Volume (mL)

Agitation
Speed (rpm)
35 rpm

500 mL

10-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm
35 rpm
500 mL

20-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm
35 rpm
500 mL

30-min

50 rpm

Drug
Dissolution
Rate

35 rpm
900 mL
50 rpm

Statistically Significant Difference
Between the Brand and Generic
Zocor (Brand)
vs.
Teva (Generic)

Zocor (Brand)
vs.
Reddy’s (Generic)

YES

NO

P < 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.05

NO

NO

P > 0.05

P > 0.05

NO

NO

P > 0.05

P > 0.05

YES

NO

P < 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.01

NO

NO

P > 0.05

P > 0.05

YES

NO

P < 0.01

P > 0.05

NO

NO

P > 0.05

P > 0.05

YES

NO

P < 0.05

P > 0.05

NO

NO

P > 0.05

P > 0.05

NO

YES

P > 0.05

P < 0.01
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DISCUSSION

Comparison of the 10-min Drug Dissolution Rates
The 10-min drug dissolution rates observed from the three marketed products of
Simvastatin 80 mg tablets manufactured by Merck (Brand Zocor), Teva (First Generic)
and Dr. Reddy's (Second Generic) dissolving in 500 mL and 900 mL volumes of three
aqueous solutions of 0.5% w/v of Sodium Lauryl Sulfate (SLS) contained in Phosphate
Buffer pH 7.0, Purified Water and Acetate Buffer pH 4.5, maintained at 37oC and
agitated by paddles rotating at 35 and 50 rpm, are compared in Tables 13-18 and plotted
as bar-graphs in Figures 21-26.
It is apparent that the majority of the 10-min drug dissolution rates exhibited by
all three Simvastatin products possess relatively high variability expressed in the form of
increased standard deviations, in all three dissolution media and in both agitation speeds
and dissolution volumes used in this study's dissolution tests. Consequently, visual
observations of the drug dissolution rate differences between the three compared products
of Simvastatin 80 mg tablets cannot ensure correct and realistic correlations between the
in-vitro and in-vivo performances of the three products. Instead, in order to ensure fair
comparisons, statistical analysis was performed using hypothesis t-testing which takes
into consideration the standard deviations of the compared drug dissolution rates.
Such statistical t-testing results of the 10-min drug dissolution rates exhibited by
the Brand Zocor and the Generic Teva or Dr. Reddy's products are tabulated in Tables
31-34 and further summarized in Tables 43-45. As shown there, statistically significant
differences between the 10-min drug dissolution rates of the Zocor vs. Teva and Zocor
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vs. Reddy's product-comparisons were observed at both 35 and 50 rpm when 500 mL of
Phosphate Buffer pH 7.0 with 0.5% w/v SLS was used as the dissolution medium, and
only for the Zocor vs. Reddy's product-comparison at 900 mL of the same medium
agitated using paddles rotating at 50 rpm. On the other hand, when 900 mL of Purified
Water with 0.5% w/v SLS was used as the dissolution medium, the 10-min dissolution
rates of the Zocor vs. Teva product-comparison presented a statistically significant
difference at 35 rpm, and those of the Zocor vs. Reddy's product-comparison at 50 rpm.
Finally, statistically significant differences between the 10-min drug dissolution rates of
the Zocor vs. Teva product-comparison were observed only at 35 rpm, and of the Zocor
vs. Reddy's product-comparison at 50 rpm, when 500 mL of Acetate Buffer pH 4.5 with
0.5% w/v SLS was used as the dissolution medium.
It should be emphasized at this point that the three Simvastatin products compared
in this study are known to be bioequivalent to each other since they have been clinically
tested and proved to be bioequivalent to each other in controlled and FDA-approved
bioequivalence studies. Therefore, dissolution testing conditions yielding 10-min drug
dissolution rates of the Zocor vs. Teva and Zocor vs. Reddy's product-comparisons that
do not exhibit statistically significant differences should be considered as dissolution
procedures that demonstrate dependable in-vitro/in-vivo correlations and are capable to
predict the in-vivo drug absorption characteristics of the products including the
bioequivalence of both of the Generic Simvastatin products (i.e., Teva and Dr. Reddy's)
to the Brand Zocor product.
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Therefore, based on this study, it seems that the 10-min Drug Dissolution Rate

can be used as a reliable predictive tool of bioequivalence between a generic Simvastatin
product and the brand Zocor, when the following dissolution testing conditions are used:
(i) 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm;
(ii) 500 mL of Purified Water with 0.5% w/v SLS, agitated at 35 rpm;
(iii) 500 mL of Purified Water with 0.5% w/v SLS, agitated at 50 rpm;
(iv) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm; and
(v) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 50 rpm.

Comparison of the 20-min Drug Dissolution Rates
The 20-min drug dissolution rates observed from the three marketed products of
Simvastatin 80 mg tablets dissolving in 500 mL and 900 mL volumes of three aqueous
solutions of 0.5% w/v of SLS contained in Phosphate Buffer pH 7.0, Purified Water and
Acetate Buffer pH 4.5, maintained at 37oC and agitated by paddles rotating at 35 and 50
rpm, are compared in Tables 19-24 and plotted as bar-graphs in Figures 27-32.
In contrast to the 10-min dissolution rates, the majority of the 20-min drug
dissolution rates exhibited by all three Simvastatin products possess relatively low
variability expressed in the form of smaller standard deviations, in all three dissolution
media, at both agitation speeds and in both dissolution volumes used in this study's
dissolution testing procedures. Consequently, visual observations of the drug dissolution
rate differences between the three compared products of Simvastatin 80 mg tablets are
more reliable in drawing correct and realistic correlations between the in-vitro and in-vivo
performances of the products. However, in order to ensure fair comparisons, statistical
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analysis was also performed using hypothesis t-testing which takes into consideration the
averages and standard deviations of the compared 20-min drug dissolution rates.
Such statistical t-testing results of the 20-min drug dissolution rates exhibited by
the Brand Zocor and the Generic Teva or Dr. Reddy's product-comparisons are tabulated
in Tables 35-38 and further summarized in Tables 43-45. As shown there, statistically
significant differences between the 20-min drug dissolution rates of only the Zocor vs.
Reddy's product-comparison were observed when both 500 and 900 mL of Phosphate
Buffer pH 7.0 with 0.5% w/v SLS was used as the dissolution medium, agitated using
paddles rotating only at 50 rpm (and not at 35 rpm). On the other hand, when 500 and
900 mL of Purified Water with 0.5% w/v SLS was used as the dissolution medium, the
20-min dissolution rates of the Zocor vs. Reddy's product-comparison presented a
statistical significant difference at both 35 and 50 rpm, and those of the Zocor vs. Teva
product-comparison at 900 mL of the same medium agitated only at 35 rpm. Finally,
statistically significant differences between the 20-min drug dissolution rates of the Zocor
vs. Teva product-comparison were observed when 500 mL of Acetate Buffer pH 4.5 with
0.5% w/v SLS was used as the dissolution medium agitated at 35 rpm and, similarly,
when 900 mL of the same medium was agitated at 50 rpm. In addition, statistically
significant differences between the 20-min drug dissolution rates of the Zocor vs. Reddy's
product-comparison were also observed when 500 mL of Acetate Buffer pH 4.5 with
0.5% w/v SLS was agitated at 50 rpm.
As discussed previously, the three Simvastatin products compared in this study
are known to be bioequivalent to each other since they have been clinically tested and
proved to be bioequivalent to each other in controlled and FDA-approved bioequivalence
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studies. Therefore, dissolution testing conditions yielding 20-min drug dissolution rates
of the Zocor vs. Teva and Zocor vs. Reddy's product-comparisons that do not exhibit
statistically significant differences should be considered as dissolution procedures that
demonstrate dependable in-vitro/in-vivo correlations and are capable to predict the in-vivo
drug absorption characteristics of the products, including the bioequivalence of both of
the Generic products (i.e., Teva and Dr. Reddy's) to the Brand Zocor product.
Therefore, based on this study, it seems that the 20-min Drug Dissolution Rate
can be used as a reliable predictive tool of bioequivalence between a generic Simvastatin
product and the brand Zocor, when the following dissolution testing conditions are used:
(i) 500 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm;
(ii) 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm; and
(iii) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm.

Comparison of the 30-min Drug Dissolution Rates
The 30-min drug dissolution rates observed from the three marketed products of
Simvastatin 80 mg tablets dissolving in 500 mL and 900 mL volumes of three aqueous
solutions of 0.5% w/v of SLS contained in Phosphate Buffer pH 7.0, Purified Water and
Acetate Buffer pH 4.5, maintained at 37oC and agitated by paddles rotating at 35 and 50
rpm, are compared in Tables 25-30 and plotted as bar-graphs in Figures 33-38.
Here again and in contrast to the 10-min dissolution rates, the 30-min drug
dissolution rates exhibited by all three Simvastatin products possess low variability
expressed in the form of very small standard deviations, in all three dissolution media, at
both agitation speeds and in both dissolution volumes used in this study's dissolution
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testing procedures.

Consequently, visual observations of the drug dissolution rate

differences between the three compared products of Simvastatin 80 mg tablets are quite
reliable in drawing correct and realistic correlations between the in-vitro and in-vivo
performances of the three products. Ultimately, however, and in order to ensure fair
comparisons, statistical analysis was also performed using hypothesis t-testing which
takes into consideration the averages and standard deviations of the compared 30-min
drug dissolution rates.
Such statistical t-testing results of the 30-min drug dissolution rates exhibited by
the Brand Zocor and the Generic Teva or Dr. Reddy's products are tabulated in Tables
39-42 and further summarized in Tables 43-45. As shown there, statistically significant
differences between the 30-min drug dissolution rates of the Zocor vs. Teva and Zocor
vs. Reddy's product-comparisons were observed when 500 mL of Phosphate Buffer pH
7.0 with 0.5% w/v SLS was used as the dissolution medium, agitated using paddles
rotating at 50 rpm. In addition, statistically significant differences between the 30-min
drug dissolution rates of the Zocor vs. Reddy's product-comparison were also observed
when 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS was agitated at 50 rpm.
On the other hand, when 500 mL of Purified Water with 0.5% w/v SLS was used as the
dissolution medium, the 30-min dissolution rates of both the Zocor vs. Teva and Zocor
vs. Reddy's product-comparisons presented a statistical significant difference at 50 rpm,
and those of the Zocor vs. Reddy's product-comparison at 500 and 900 mL of the same
medium agitated at 35 rpm. Finally, statistically significant differences between the 30min dissolution rates of the Zocor vs. Teva product-comparison were observed when 500
mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS was used as the dissolution medium
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agitated at 50 rpm, and between the 30-min drug dissolution rates of the Zocor vs.
Reddy's product-comparison when 900 mL of the same dissolution medium was agitated
at 50 rpm.
As discussed previously, the three Simvastatin products compared in this study
are known to be bioequivalent to each other since they have been clinically tested and
proved to be bioequivalent to each other in controlled and FDA-approved bioequivalence
studies. Therefore, dissolution testing conditions yielding 30-min drug dissolution rates
of the Zocor vs. Teva and Zocor vs. Reddy's product-comparisons that do not exhibit
statistically significant differences should be considered as dissolution procedures that
demonstrate dependable in-vitro/in-vivo correlations and are capable to predict the in-vivo
drug absorption characteristics of the products, including the bioequivalence of both of
the Generic products (i.e., Teva and Dr. Reddy's) to the Brand Zocor product.
Therefore, based on this study, it seems that the 30-min Drug Dissolution Rate
can be used as a reliable predictive tool of bioequivalence between a generic Simvastatin
product and the brand Zocor, when the following dissolution testing conditions are used:
(i) 500 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm;
(ii) 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm;
(iii) 900 mL of Purified Water with 0.5% w/v SLS, agitated at 50 rpm;
(iv) 500 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm; and
(v) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm.
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CONCLUSION

This study reveals that similarities of the 10-min, 20-min and 30-min drug
dissolution rates exhibited by the three bioequivalent products investigated in this study,
are basically dependent upon the type of dissolution media and conditions used to test
these three Simvastatin products. Specifically, it appears that the drug solubility in the
dissolution medium used, as expressed by the volume, acidity and buffer capacity of the
medium, play an important role in creating a testing environment which may yield similar
drug dissolution rates of the tested products, as expected to be the case since all three
products have been already proven in controlled and FDA-approved clinical studies to be
bioequivalent to each other.
In essence, one should investigate whether any of the three dissolution media used
in this study, under any dissolution conditions employed in this study, were able to
simultaneously produce 10-min, 20-min and 30-min drug dissolution rates of the branded
Zocor product that were statistically similar to those of both the generic Teva and Dr.
Reddy's Simvastatin products. If such dissolution medium and testing conditions exist,
then this study can be considered as one that resulted in the establishment of a dissolution
test which may present dependable in-vitro/in-vivo correlations and reliable predictive
power of bioequivalence.
Based on the work conducted and results obtained in this study, it seems that two
such dissolution tests have been discovered in this research project as shown in Tables 43
and 45 and further described in the foregoing Discussion section. The following two
dissolution tests predict bioequivalence:
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(1)

900 mL (per vessel) of an aqueous medium containing 0.5% w/v SLS in
Phosphate Buffer pH 7.0 (i.e., the USP dissolution medium), maintained
at 37oC and agitated at 35 rpm (via paddles); and/or

(2)

900 mL (per vessel) of an aqueous medium containing 0.5% w/v SLS in
Acetate Buffer pH 4.5, maintained at 37oC and agitated at 35 rpm (via
paddles).

In conclusion, if a laboratory attempts to develop a new generic product of
Simvastatin 80 mg Tablets that are bioequivalent to the branded Zocor Simvastatin 80 mg
Tablets, then the new product must be formulated in such a way that, when tested for its
dissolution profile using 900 mL (per vessel in which one tablet is dissolved/tested) of an
aqueous medium containing either 0.5% w/v SLS in Phosphate Buffer pH 7.0 and/or
0.5% w/v SLS in Acetate Buffer pH 4.5, maintained at 37oC and agitated using paddles
rotating at 35 rpm, its 10-min, 20-min and 30-min drug dissolution rates should be
statistically similar to those obtained from the same testing of the branded Zocor 80 mg
Tablets.
If the above conclusions are correct and these two dissolution testing procedures
can appropriately predict bioequivalence between a new, experimental generic
Simvastatin product and its commercial branded Zocor counterpart, then the dissolution
tests discovered and proposed in this work may be used as invaluable formulation tools in
order to develop new generic products in a timely and cost-efficient manner of
Simvastatin 80 mg Tablets.
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